Data on the combination of eribulin and trastuzumab (E/T) are limited, although recent analyses demonstrated safety and efficay for its use. The aim of this observational, retrospective, multicenter study was to examine the tolerability and the clinical activity of eribulin plus trastuzumab in the treatment of HER2 positive ABC.
Patients (pts) treated with eribulin mesylate (1.23 mg/m2 on days 1 and 8 of a 21-day cycle) plus standard dosing of trastuzumab (16 pts received 3-week schedule: 8 mg/kg load, 6 mg/kg q 3 weeks; 8 pts received weekly schedule: 4 mg/kg load, 2 mg/kg q week) in 6 Italian oncology units were include. Data on response rate (RR), overall survival (OS) and safety were reported.
Between October 2012 and November 2015 twenty four pts with HER2-positive ABC were included. Median age was 57 years (32 to 74). All patients were heavily pretreated: the median number of prior chemotherapy (CT) regimens for MBC was 3 (range 2-9). ECOG PS pre-E/T treatment was 0-1 in 75%. The median number of cycles with E/T was 11,5 (range 2-26). Complete response (CR) was achieved in 1 pts (4,2%), 9 pts (37,5%) achieved partial response (PR), 9 pts (37,5%) had stable disease (SD), and 5 pts (20,8%) had progressive disease (PD). Median OS was 7,7 months (range 2,8-30,5). Comorbidities at study entry were cardiovascular (including hypertension), 54.2%; diabetes, 8.3%; other diseases, 16.7%. Neutropenia was the most common clinical grade 3/4 adverse event (25%); one case (4,2%) of febrile neutropenia was observed. Main grade 3/4 non hematological toxicities were fatigue (4,2%), peripheral neuropathy (4,2%) and nausea (4,2%). Alopecia was observed in more than half of pts (66,7%). Dose reduction was applied in 6 pts (25%); three pts (12,5%) interrupted the treatment prematurely.
Tolerability and efficacy of E/T combination schedule are encouraging . The results of this study indicated that this combination might be considered for future prospective study.
Clinical trial identification
Legal entity responsible for the study
Medical Oncology Group Ospedale Perrino Brindisi
All authors have declared no conflicts of interest.